Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors

Oncotarget

Volumn 5, Issue 10, 2014, Pages 3023-3028

  Antolín, Albert A ^a   Mestres, Jordi ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Biomarkers; Drug combinations; Kinase profiling; Off target pharmacology; PARP inhibitors

Indexed keywords

3 AB; ALK KINASE; CASEIN KINASE II; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 9; DYRK1A KINASE; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NU 1085; OLAPARIB; PIM2 KINASE; PRKD2 KINASE; PROTEIN KINASE; PROTEIN KINASE PIM 1; RUCAPARIB; S6 KINASE; UNCLASSIFIED DRUG; VELIPARIB; 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; INDOLE DERIVATIVE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; IC 50; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPUTER SIMULATION;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; COMPUTER SIMULATION; ENZYME INHIBITORS; HUMANS; INDOLES; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84901221201     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1814     Document Type: Article

References (36)

1. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361: 123-34.
2. Guha M. PARP inhibitors stumble in breast cancer. Nat Biotechnol. 2011; 29: 373-4.
3. Garber K. PARP inhibitors bounce back. Nat Rev Drug Discov. 2013; 12: 725-7.
4. Polyak K, Garber J. Targeting the missing links for cancer therapy. Nat Med. 2011; 17: 283-4.
5. Ma W, Halweg CJ, Menendez D, Resnick MA. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci USA. 2012; 109: 6590-5.
6. Chuang H-C, Kapuriya N, Kulp SK, Chen C-S, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat. 2012; 134: 649-59.
7. Murai J, Huang S-YN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72: 5588-99.
8. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research. 2012; 41: D955-D961.
9. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell A-G, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012; 30: 283-8.
10. Antolín AA, Jalencas X, Yélamos J, Mestres J. Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem Biol. 2012; 7: 1962-7.
11. Ferraris DV. Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic. J Med Chem. 2010; 53: 4561-84.
12. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012; 40: D1100-1107.
13. Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ. Navigating the kinome. Nat Chem Biol. 2011; 7: 200-2.
14. Couty S, Westwood IM, Kalusa A, Cano C, Travers J, Boxall K, et al. The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget. 2013; 4: 1647-61.
15. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008; 7: 1368-77.
16. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA. 2010; 107: 14621-6.
17. Li D, Jackson RA, Yusoff P, Guy GR. Direct association of Sprouty-related protein with an EVH1 domain (SPRED) 1 or SPRED2 with DYRK1A modifies substrate/kinase interactions. J Biol Chem. 2010; 285: 35374-85.
18. Shi X, Zhang H, Paddon H, Lee G, Cao X, Pelech S. Phosphorylation of STAT3 serine-727 by cyclin-dependent kinase 1 is critical for nocodazole-induced mitotic arrest. Biochemistry. 2006; 45: 5857-67.
19. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011; 11: 23-34.
20. Gagné J-P, Moreel X, Gagné P, Labelle Y, Droit A, Chevalier-Paré M, et al. Proteomic investigation of phosphorylation sites in poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase. J Proteome Res. 2009; 8: 1014-29.
21. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2013 [Epub ahead of print].
22. Red Brewer M, Pao W. Maximizing the benefits of off-target kinase inhibitor activity. Cancer Discov. 2013; 3: 138-40.
23. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, et al. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discov. 2013; 3: 1416-29.
24. Rehman FL, Lord CJ, Ashworth A. The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy. Cancer Discov. 2012; 2: 982-4.
25. Johnson N, Li Y-C, Walton ZE, Cheng KA, Li D, Rodig SJ, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med. 2011; 17: 875-82.
26. Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle. 2013; 12: 877-83.
27. Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, et al, Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and-independent DNA damage responses induced by DNA damaging agent. Cell Cycle. 2011; 10: 4074-82.
28. van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget. 2011; 2: 984-96.
29. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, et al. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene. 2009; 28: 2581-92.
30. Siemeister G, Lücking U, Wengner AM, Lienau P, Steinke W, Schatz C, et al. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono-and in combination treatment upon oral application. Mol Cancer Ther. 2012; 11: 2265-73.
31. Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, et al. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res. 2009; 11: R12.
32. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009; 27: 2705-11.
33. Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res. 2012; 72: 4796-806.
34. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen Aet al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008; 14: 7917-23.
35. http://www.clovisoncology.com/files/CLVS_ASCO_2013_poster_rucaparib_P1monotx_abstract2585.pdf.
36. Lin H, Sassano MF, Roth BL, Shoichet BK. A pharmacological organization of G protein-coupled receptors. Nat Methods. 2013; 10: 140-6. .